4Q2025FDA Decision for Ozempic (semaglutide 1 mg & 2 mg) in T2DM and PAD
4Q2025FDA Decision for Wegovy SC (semaglutide) in HFpEF and Obesity
4Q2025FDA Decision for Oral Wegovy 25 mg
Drivers
Generic competition signals
Stable but not accelerating oral scripts
Trend
10-13
10-13
10-13
10-15
10-15
10-15
10-17
Competition intensifies with Sandoz generic tirzepatide progress and ongoing compounding policy shifts, reinforcing medium-term margin pressure despite market expansion.
Novo continues to expand Wegovy indications (e.g., China MASH approval) and oral rollout (Germany launch), while real-world data supports targeted use. However, Lilly's superior combo data and broader industry AI/obesity deals underscore intensifying competition. Oral script trends show Lilly gaining share, aligning with margin compression risks.
Background
Tracking began on 2026-03-20.
Your thesis: Bearish medium-term: GLP-1 competition from Lilly and Amgen will compress margins despite market growth
Recent Developments
Novo Nordisk settles US patent dispute with Viatris over Ozempic and Wegovy3h ago
Neutral: Settlement reduces near-term litigation risk but does not alter underlying generic competition timeline or margin pressure from Lilly and others.
FDA submits interim peptide compounding policy to White House13h ago
Neutral: Expands compounding landscape but primarily affects non-GLP-1 peptides; indirect signal of broader regulatory flexibility that could eventually impact GLP-1 compounding dynamics.
Sandoz generic tirzepatide applications accepted by FDA13h ago
Reinforces thesis: Accelerating generic competition in the GLP-1 market (beyond semaglutide) will intensify pricing and margin pressure on originators like Novo and Lilly.
Novo Nordisk signs up to $1.3B Nanexa deal for long-acting injectable technology1d ago
Neutral: Manufacturing innovation supports long-term supply chain resilience but does not directly address near-term margin compression from competition.
It gets worse when you decompose it. The US is 4.2% of world population and 31.5% of world household consumption... Novo Nordisk gets 58% of its sales from the US...